HPLC SERUM ANALYSES WITHOUT PRIOR PROTEIN REMOVAL

Award Information
Agency:
Department of Health and Human Services
Amount:
$429,000.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1988
Phase:
Phase II
Agency Tracking Number:
4953
Solicitation Topic Code:
N/A
Small Business Information
Regis Chemical Company
8210 North Austin Avenue, Morton Grove, IL, 60053
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 John A Perry
 Principal Investigator
 (312) 967-6000
Business Contact
Phone: () -
Research Institution
N/A
Abstract
DRUGS NOW DETERMINED IN SERUM-HUNDREDS OF THOUSANDS OF SAMPLES PER YEAR IN THE UNITED STATES ALONE-BY HIGH-PRESSURELIQUID CHROMATOGRAPHY (HPLC). PROTEIN MUST FIRST BE REMOVEDFROM THE SERUM, OTHERWISE THE HPLC COLUMNS ARE QUICKLY RUINED. INTERNAL-SURFACE REVERSED-PHASE (ISRP) HPLC COLUMNSAFFORD SUCH DETERMINATIONS WITHOUT REQUIRING THE PRIOR REMOVAL OF PROTEIN FROM THE SERUM. WITH PHASE I ASSISTANCE,REGIS SYNTHESIZED THE FIRST COMMERCIAL ISRP, GLYCINE- PHENYLALANINE-PHENYLALANINE (GFF); PUT ITS SYNTHESIS ON A PRODUCTION BASIS; CHARACTERIZED GFF; BROUGHT REPRODUCIBLE, EFFICIENT, LONG-LIVED, AND SELECTIVE GFF ISRP HIGH- EFFICIENCY HPLC COLUMNS TO MARKET; DEMONSTRATED SEVERAL REAL-LIFE ISRP GFF APPLICATIONS; AND PUBLICIZED THE EFFORT IN A VARIETY OF WAYS. WITH PHASE II ASSISTANCE, REGIS WILL DEVELOP FURTHER DEMONSTRATIVE APPLICATIONS OF GFF AND RE- STUDY THE SYNTHESIS SO AS TO PRODUCE BETTER SUCCESSORS. COMPLEMENTARY ISRPS WILL THEN BE SYNTHESIZED, CHARACTERIZED,INTRODUCED, AND SUPPORTED. ALSO, CONCEPTUALLY NEW ISRPS WILL BE SYNTHESIZED FOR APPLICATIONS NOW BEYOND ROUTINE REACH; ISRPS THAT AFFORD CHIRAL SEPARATIONS FREE-DRUG VERSUSBOUND-DRUG DETERMINATIONS, AND PREPARATIVE SEPARATIONS FOR BIOTECHNOLOGY.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government